CDP recognizes Almirall for its commitment to fight against climate change

Almirall S.A. (ALM) has reached a new achievement by upgrading its leadership score on the 2020 ranking of the Climate Change in CDP, an international reference organization for assessing the environmental impact of companies. Thus, the company has demonstrated its commitment to keep fighting climate change through two main pillars: reducing the carbon footprint and the role that the company wants to play in preventing and minimizing the damage that climate change can cause on people’s health.

Since 2014, Almirall has been reporting its environmental performance on climate change to CDP and has managed to improve from score C level of Awareness in 2018, then onward to B level of Management in 2019 and now, in 2020, to the important milestone of A⁻ Level Leadership. Almirall is amongst 38% of the world’s largest companies that reached Leadership level in the Biotech and Pharma industries, which is higher than the Europe regional average of C. This disclosure is a measure of effective management of carbon and climate change risk and an exercise of transparency and accountability essential to tracking progress towards a sustainable future. The report has been made by CDP, a not-for-profit charity that runs a global disclosure system for investors, companies, cities, states, and regions to manage their environmental impacts. The world’s economy looks to CDP as the gold standard of environmental reporting with the richest and most comprehensive dataset on corporate action.

Almirall’s commitment to the planet

The first pillar of Almirall’s strategy to fight climate change (reduce the carbon footprint) is materializing in a sustainable use of resources, including energy efficiency and the reduction of electricity and gas consumption in their facilities, which are its main sources of energy. Since 2016, the company has installed photovoltaic panels at the chemical plant in Sant Celoni (300 kW) and at the pharmaceutical plant in Sant Andreu de la Barca (800 kW) and has entered into a contract at its facilities in Spain and Germany to purchase electricity from renewable sources with Guarantee of Origin. Altogether, Almirall increased its renewable energy consumption by 474% since 2017.

Almirall strongly supports the Paris Agreement and want to be part of the solution by doing everything they can to keep the rise in average global temperature well below 2°C above pre-industrial levels. To reach that goal, the company has established the commitment to reduce greenhouse gas emissions by 21% in the year 2025 compared to 2014, which represents a reduction of 3.355 metric tons of CO2 released into the atmosphere.

Almirall is committed to developing its corporate strategy aligned to its commitment to environmental protection. The company has reduced the diffuse emissions of Volatile Organic Compounds (VOCs) from its activity by more than 75% since 2017. Furthermore, Almirall's processes are designed to contribute to the progressive minimization of water consumption. In all its centers, the parameters average at a minimum below 70% of the legal. Also, the products are manufactured with sustainability in mind following an eco-design perspective, from the R&D stage to distribution, in order to reduce their environmental impact.

This objective is another one in which Almirall shows its social responsibility and responds to the demands made by society, achieving an operational balance while at the same time generating competitiveness. The patient is at the center of everything Almirall does. The company strives to create new products that improve their lives through research, innovation, and the strictest compliance with ethical and legal standards.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com